Cargando…

TRAIL receptor agonists convert the response of breast cancer cells to ONC201 from anti-proliferative to apoptotic

ONC201 was initially identified as an inducer of cell death through the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) pathway. The compound is currently being tested in patients with hematological malignancies and solid tumors, including those of the breast. We investigated strateg...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ralff, Marie D., Jhaveri, Aakash, Ray, Jocelyn E., Zhou, Lanlan, Lev, Avital, Campbell, Kerry S., Dicker, David T., Ross, Eric A., El-Deiry, Wafik S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2020
Materias:	Priority Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7584235/ https://www.ncbi.nlm.nih.gov/pubmed/33144917 http://dx.doi.org/10.18632/oncotarget.27773

Ejemplares similares

Antitumorigenic effect of combination treatment with ONC201 and TRAIL in endometrial cancer in vitro and in vivo
por: Ray, Jocelyn E., et al.
Publicado: (2021)

Anti-pancreatic cancer activity of ONC212 involves the unfolded protein response (UPR) and is reduced by IGF1-R and GRP78/BIP
por: Lev, Avital, et al.
Publicado: (2017)

Role of Dopamine Receptors in the Anticancer Activity of ONC201()()
por: Kline, Christina Leah B., et al.
Publicado: (2017)

Combination of ONC201 and TLY012 induces selective, synergistic apoptosis in vitro and significantly delays PDAC xenograft growth in vivo
por: Jhaveri, Aakash V., et al.
Publicado: (2021)

Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway
por: Allen, Joshua E, et al.
Publicado: (2015)

ONC201 and imipridones: Anti-cancer compounds with clinical efficacy
por: Prabhu, Varun Vijay, et al.
Publicado: (2020)

The angular structure of ONC201, a TRAIL pathway-inducing compound, determines its potent anti-cancer activity
por: Wagner, Jessica, et al.
Publicado: (2015)

Discovery and clinical introduction of first-in-class imipridone ONC201
por: Allen, Joshua E., et al.
Publicado: (2016)

Correction: Discovery and clinical introduction of first-in-class imipridone ONC201
por: Allen, Joshua E., et al.
Publicado: (2021)

Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors
por: Prabhu, Varun V., et al.
Publicado: (2017)

Anti-tumor effects of ONC201 in combination with VEGF-inhibitors significantly impacts colorectal cancer growth and survival in vivo through complementary non-overlapping mechanisms
por: Wagner, Jessica, et al.
Publicado: (2018)

Identification of Smurf2 as a HIF-1α degrading E3 ubiquitin ligase
por: Zhao, Shuai, et al.
Publicado: (2021)

Anti-cancer efficacy including Rb-deficient tumors and VHL-independent HIF1α proteasomal destabilization by dual targeting of CDK1 or CDK4/6 and HSP90
por: Zhao, Shuai, et al.
Publicado: (2021)

A multiplexed marker-based algorithm for diagnosis of carcinoma of unknown primary using circulating tumor cells
por: Matthew, Elizabeth M., et al.
Publicado: (2015)

Application of 3D tumoroid systems to define immune and cytotoxic therapeutic responses based on tumoroid and tissue slice culture molecular signatures
por: Finnberg, Niklas K., et al.
Publicado: (2017)

First-In-Class Small Molecule ONC201 Induces DR5 and Cell Death in Tumor but Not Normal Cells to Provide a Wide Therapeutic Index as an Anti-Cancer Agent
por: Allen, Joshua E., et al.
Publicado: (2015)

BRCA2, EGFR, and NTRK mutations in mismatch repair-deficient colorectal cancers with MSH2 or MLH1 mutations
por: Deihimi, Safoora, et al.
Publicado: (2017)

Correction: First-In-Class Small Molecule ONC201 Induces DR5 and Cell Death in Tumor but Not Normal Cells to Provide a Wide Therapeutic Index as an Anti-Cancer Agent
por: Allen, Joshua E., et al.
Publicado: (2016)

ONC212 is a Novel Mitocan Acting Synergistically with Glycolysis Inhibition in Pancreatic Cancer
por: Ferrarini, Isacco, et al.
Publicado: (2021)

Regulation of the human TRAIL gene
por: Allen, Joshua E., et al.
Publicado: (2012)

A subset of CB002 xanthine analogs bypass p53-signaling to restore a p53 transcriptome and target an S-phase cell cycle checkpoint in tumors with mutated-p53
por: Hernandez Borrero, Liz, et al.
Publicado: (2021)

Sorafenib Sensitizes Solid Tumors to Apo2L/TRAIL and Apo2L/TRAIL Receptor Agonist Antibodies by the Jak2-Stat3-Mcl1 Axis
por: Abdulghani, Junaid, et al.
Publicado: (2013)

EZH2i EPZ-6438 and HDACi vorinostat synergize with ONC201/TIC10 to activate integrated stress response, DR5, reduce H3K27 methylation, ClpX and promote apoptosis of multiple tumor types including DIPG
por: Zhang, Yiqun, et al.
Publicado: (2021)

DIPG-57. TRANSCRIPTOMIC AND PROTEOMIC ANALYSES OF DIPG RESPONSE TO ONC201
por: Sridharan, Sreepradha, et al.
Publicado: (2020)

Small Molecular TRAIL Inducer ONC201 Induces Death in Lung Cancer Cells: A Preclinical Study
por: Feng, Yuan, et al.
Publicado: (2016)

Pan-drug and drug-specific mechanisms of 5-FU, irinotecan (CPT-11), oxaliplatin, and cisplatin identified by comparison of transcriptomic and cytokine responses of colorectal cancer cells
por: Carlsen, Lindsey, et al.
Publicado: (2021)

P53-independent partial restoration of the p53 pathway in tumors with mutated p53 through ATF4 transcriptional modulation by ERK1/2 and CDK9
por: Tian, Xiaobing, et al.
Publicado: (2021)

MEK inhibitors reduce cellular expression of ACE2, pERK, pRb while stimulating NK-mediated cytotoxicity and attenuating inflammatory cytokines relevant to SARS-CoV-2 infection
por: Zhou, Lanlan, et al.
Publicado: (2020)

HGG-36. ONC201 TARGETING IN DIPG
por: Abuarqoub, Alqassem, et al.
Publicado: (2021)

Circulating tumor cells: silent predictors of metastasis
por: Zhou, LanLan, et al.
Publicado: (2017)

ONC201-Induced Mitochondrial Dysfunction, Senescence-like Phenotype, and Sensitization of Cultured BT474 Human Breast Cancer Cells to TRAIL
por: Mishukov, Artem, et al.
Publicado: (2022)

Efficacy of ONC201 in Desmoplastic Small Round Cell Tumor()
por: Hayes-Jordan, Andrea A., et al.
Publicado: (2018)

HGG-44. REVEALING VULNERABILITIES IN DIPG THROUGH ONC201
por: Stafford, James, et al.
Publicado: (2021)

Therapeutic targeting of TRAIL death receptors
por: Di Cristofano, Francesca, et al.
Publicado: (2023)

Comparison of SARS-CoV-2 RT-PCR on a high-throughput molecular diagnostic platform and the cobas SARS-CoV-2 test for the diagnostic of COVID-19 on various clinical samples
por: Opota, Onya, et al.
Publicado: (2020)

Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration
por: Stein, Mark N., et al.
Publicado: (2019)

Systematic drug perturbations on cancer cells reveal diverse exit paths from proliferative state
por: Zhou, Joseph X., et al.
Publicado: (2016)

TIC10/ONC201: a bend in the road to clinical development
por: Greer, Yoshimi Endo, et al.
Publicado: (2015)

ONC201 kills breast cancer cells in vitro by targeting mitochondria
por: Greer, Yoshimi Endo, et al.
Publicado: (2018)

Apoptotic circulating tumor cells (CTCs) in the peripheral blood of metastatic colorectal cancer patients are associated with liver metastasis but not CTCs
por: Allen, Joshua E., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_i2eh22agh1cnufjjviddfsm86n